A syndrome of osteoporosis, increased serum immunoreactive parathyroid hormone, and inappropriately low serum 1,25-dihydroxyvitamin D. 1978

B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud

Although most patients with postmenopausal osteoporosis have normal or low values for serum immunoreactive parathyroid hormone (iPTH), we have reported previously that a small subset (about 10% of the total group) have increased values. We studied three patients representative of this latter group. Serum iPTH was two to three times higher than the age-adjusted normal mean, serum ionized calcium and total calcium were in the lower half of the normal range, and serum 1,25-dihydroxyvitamin D [1,25(OH)2D] was in the low-normal range. Six months of treatment of one patient with 0.5 microgram/day of synthetic 1,25(OH)2D improved calcium absorption and balance; however, serum iPTH remained high. After surgical removal of 1,010 mg of hyperplastic parathyroid tissue, serum iPTH decreased to normal. These and other data suggest that increased serum iPTH in these patients was caused by secondary hyperparathyroidism, possibly because of inadequate conversion of 25-OH-D to 1,25(OH)2D.

UI MeSH Term Description Entries
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006887 Hydroxycholecalciferols Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3. Hydroxyvitamins D,Hydroxycholecalciferol
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen

Related Publications

B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud
August 1997, Calcified tissue international,
B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud
January 1994, Mineral and electrolyte metabolism,
B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud
February 1980, Annals of internal medicine,
B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud
June 1990, Clinical rheumatology,
B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud
April 1989, The Journal of clinical investigation,
B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud
September 1984, The American journal of clinical nutrition,
B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud
October 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud
August 1980, The American journal of physiology,
B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud
February 1980, Lancet (London, England),
B L Riggs, and J C Gallagher, and H F DeLuca, and A J Edis, and P W Lambert, and C D Arnaud
July 1988, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!